Image by Freepik
In a mouse study, it was shown that the mitochondrial antioxidant MitoQ, which is sold as a dietary supplement, can counteract the negative effects that HIV and antiretroviral therapy (ART) have on the mitochondria in the brain, heart, aorta, lungs, kidney, and liver.
The ratio of nuclear DNA (ntDNA) to mitochondrial DNA (mtDNA) in humans and mice was calculated using a molecular technique as a marker of mitochondrial dysfunction. This ratio’s decline indicates a mitochondrial malfunction.
HIV-infected mice receiving ART showed mitochondrial dysfunction in the human immune cells in the brain, heart, liver, lungs, and gut compared to uninfected mice. In mouse heart cells, mitochondrial function was likewise impacted by ART.
Compared to HIV-infected mice on ART, those treated with MitoQ for 90 days had less mitochondrial dysfunction in their organs.
The major cellular components known as mitochondria are crucial for the efficient operation of organs like the brain, heart, liver, and kidney. Chronic immunological dysfunction and inflammation brought on by HIV contribute to organ damage. Although the causes of this are unknown, it is known that mitochondrial dysfunction, which is present in chronic HIV, contributes to organ damage. HIV-related illnesses that impact organs like the liver, heart, and brain do not have any treatments available.
Humanized mice were utilized by the researchers because they have human immune cells that are susceptible to HIV infection.
They gave them the virus, treated them with ART using emtricitabine, raltegravir, and tenofovir disoproxil fumarate, and then gave them MitoQ through their water for three months. MitoQ wasn’t administered to the control mice.
The scientists point out that humanized mice do not precisely mimic human HIV infection. Furthermore, because the infected mice were exposed to both the virus and the ART, it was impossible to determine how much, exactly, the virus vs the ART contributed to mitochondrial dysfunction in human cells.
These preliminary results might be the basis for HIV-positive human clinical trials.
“MitoQ is a diet supplement that is known to be safe in humans and is readily available for use,” said senior author Dr. Theodoros Kelesidis, associate professor of medicine in the division of infectious diseases at the David Geffen School of Medicine at UCLA.
Our findings support clinical trials of MitoQ in people with HIV who take antiretrovirals to determine whether it can be a potential treatment for comorbidities associated with chronic HIV infection. Until then people with HIV should not take this diet supplement for treatment of any conditions associated with HIV infection.”
The study is published in the Journal of Infectious Diseases.
more recommended stories
Retinal Neurodegeneration in Parkinson’s DiseaseBy measuring the thickness of the.
Epilepsy Seizures: Role of Astrocytes in Neural HyperactivityRoughly 1% of people experience epilepsy.
Role of Engineered Peptides in Cancer ImmunotherapyIn a recent publication in Nature.
CRISPR-Cas9 Gene Therapy for Prostate CancerIn their preclinical model, the researchers.
Epilepsy Surgery: Rare Hemorrhagic Complications StudyFollowing cranial Epilepsy Surgery, hemorrhagic complications.
Pediatric Epilepsy – Mental Health Interventions UnveiledMental health challenges frequently manifest in.
Neoadjuvant Chemotherapy Boosts Ovarian CancerDuring the COVID-19 pandemic, US women.
Brain Connectivity Unveils New Insights into AutismBecause autism spectrum disease symptoms can.
AI Tool Predicts Cancer Therapy Responses Using Tumor Cell DataWith over 200 types of cancer,.
Nutrient Optimization: Vitamin D for HealthResearchers addressed the prevalence of vitamin.
Leave a Comment